What is Ascletis Pharma?
Ascletis Pharma Inc. operates as a fully integrated biotechnology enterprise, distinguished by its focus on metabolic disease therapeutics. By leveraging advanced methodologies such as Artificial Intelligence-assisted Structure-Based Drug Discovery and an Ultra-Long-Acting Platform, the company develops a robust portfolio of small molecules and peptides. These innovations are specifically engineered to tackle chronic weight management and complex immune disorders. Listed on the Hong Kong Stock Exchange, Ascletis serves as a critical link between cutting-edge scientific research and practical healthcare solutions, providing healthcare providers and patients with high-efficacy treatment options. The company's market position is bolstered by its commitment to bridging the gap between laboratory discovery and clinical application, ensuring that its therapeutic candidates meet rigorous global standards.
How much funding has Ascletis Pharma raised?
Ascletis Pharma has raised a total of $255M across 4 funding rounds:
Series A
$100M
Private Equity
$35M
Unspecified
$20M
Series B
$100M
Series A (2011): $100M, investors not publicly disclosed
Private Equity (2015): $35M led by Tasly Pharmaceuticals, Inc and CBC Group
Unspecified (2015): $20M supported by Goldman Sachs
Series B (2017): $100M featuring Tasly Pharmaceuticals, Inc, CBC Group, and Goldman Sachs
Key Investors in Ascletis Pharma
Tasly Pharmaceuticals, Inc
A China-based conglomerate with a global footprint, Tasly focuses on pharmaceutical manufacturing and distribution, leveraging decades of experience in medical and scientific innovation.
CBC Group
One of the largest healthcare-dedicated investment firms in Asia, CBC Group specializes in platform-building and transformative buyouts within the biotech and medtech sectors.
Goldman Sachs
A premier global investment banking and management firm that provides essential financial advisory, underwriting, and strategic capital to support the growth of high-potential enterprises.
What's next for Ascletis Pharma?
With the support of this major strategic investment, Ascletis Pharma is well-positioned to scale its research and development operations. The company's forward-looking strategy centers on the advancement of its clinical-stage assets and the expansion of its commercial footprint. By utilizing its AI-driven discovery engine, Ascletis aims to shorten the development cycle for its pipeline, potentially disrupting the current market for metabolic disease treatments. Future growth will likely focus on strengthening its intellectual property portfolio and exploring international partnerships to facilitate the global distribution of its therapeutic candidates. As the company matures, its ability to maintain operational excellence while navigating the complexities of the pharmaceutical regulatory environment will be paramount to sustaining its long-term growth trajectory.
See full Ascletis Pharma company page
